Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2160051 | 0.80 | DCLRE1B (0.60) | DCLRE1BESR2HCAR2 | |
| SCHEMBL29363677 | 0.80 | DCLRE1B (0.60) | DCLRE1BESR2HCAR2 | |
| SCHEMBL14783967 | 0.79 | ESR2 (0.50) | DCLRE1BESR2TAAR1CES2CES1 | |
| SCHEMBL12352001 | 0.79 | MAP4K4 (0.56) | DCLRE1BESR2TAAR1CES2CES1 | |
| SCHEMBL29188757 | 0.75 | SLC6A4 (0.49) | DCLRE1BESR2TAAR1PTGER2 | |
| SCHEMBL18759259 | 0.74 | CYP1A2 (0.56) | DCLRE1BESR2TAAR1MAP4K4CYP3A4 | |
| SCHEMBL14786153 | 0.74 | TRPM8 (0.53) | DCLRE1BESR2TAAR1PTGER2MAP4K4 | |
| SCHEMBL14252243 | 0.71 | DCLRE1B (0.67) | DCLRE1BESR2TAAR1HCAR2 | |
| SCHEMBL14241077 | 0.71 | MAPT (0.56) | DCLRE1BFFAR1 | |
| SCHEMBL16619526 | 0.71 | CES2 (0.61) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624159-B2 | Aniline derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2017-04-18 | — | — | US | disclosed |
| US-20160199330-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2016-07-14 | — | — | US | disclosed |
| US-9249085-B2 | Aniline derivatives, their preparation and their therapeutic application | FOVEA PHARMACEUTICALS (FR) | 2016-02-02 | — | — | US | disclosed |
| US-20140350019-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350019-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | CYP11B1, CYP11B2, ARG2 | DCLRE1B 4648/4885ESR2 1310/4885TAAR1 834/4885 |
| US-20160199330-A1 | ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | CYP11B1, ARG2, CYP11B2 | DCLRE1B 4593/4885ESR2 1213/4885TAAR1 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.